ArticleEmerging microbes & infections2026
A highly potent, stable, and safe dePEGylated lipopeptide against Nipah virus and related henipaviruses.
Article in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nipah virus (NiV) poses a significant threat owing to its high mortality and the lack of approved therapeutics. Targeting the conserved heptad repeat 1 (HR1) domain of the viral fusion (F) protein constitutes a promising antiviral strategy. Also, lipopeptides derived from the human parainfluenza virus 3 (HPIV3) heptad repeat 2 (HR2) regions inhibit NiV fusion by blocking formation of the critical six-helix bundle (6-HB); however, their efficacy has been impeded by the controversial use of PEGylation. To resolve these limitations, we employed our proprietary heptad repeat 2 C-terminal fragment (HR2-CF) peptide displacement strategy that eliminates PEG and overcomes the resultant steric hindrance. The lead dePEGylated lipopeptide, VQ-P1-C16, exhibited antiviral activity comparable to that of PEGylated lipopeptide, VIKI-PEG4-C16. Further introducing Glu (E) or Lys (K) mutations yielded VQ-P1-EK3-C16, which exhibited ultra-potent pseudotyped henipavirus inhibition at pM concentrations and increased fusion inhibition. Meanwhile, it protected newborn mice from pseudotyped NiV-Malaysia and NiV-Bangladesh infection in lungs and brains. Structural simulations and mechanistic studies demonstrated that VQ-P1-EK3-C16 adopts a helical conformation, exhibits high affinity for NiV-HR1, and inhibits NiV 6-HB formation. Moreover, VQ-P1-EK3-C16 showed significantly increased solubility, improved thermal stability, strengthened resistance to proteases, and extended serum half-life. These findings establish VQ-P1-EK3-C16 as a highly potent, stable, and safe fusion inhibitor with promising potential for the clinical development of therapeutics against NiV and related henipaviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.